


Claims

1. Use of the compounds of the following formula (I):



wherein X represents OH, (C<sub>1-5</sub>)alkoxy, NH<sub>2</sub>, NH-C<sub>1-5</sub>-alkyl, N(C<sub>1-5</sub> alkyl)<sub>2</sub>;


R<sub>1</sub> is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C<sub>1-5</sub>) alkoxy group, a (C<sub>1-5</sub>) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

R<sub>2</sub> is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn;

R<sub>3</sub> and R<sub>4</sub> independently represent H, OH, (C<sub>1-5</sub>)alkyl, or (C<sub>1-5</sub>)alkoxy, provided that R<sub>3</sub> and R<sub>4</sub> are not both OH or (C<sub>1-5</sub>)alkoxy;

R<sub>5</sub> represents H, OH, (C<sub>1-5</sub>) alkyl or (C<sub>1-5</sub>)alkoxy;

and wherein R<sub>0</sub> represents a group of the formula



wherein Y represents  $-CO-$ ,  $-CH_2CO-$ ,  $-CH_2CH_2CO-$ ,  $-CH_2CH_2CH_2CO-$ ,  $-CH=CH-CO$  or  $-OCH_2CO-$ , and wherein Z represents a halogen atom, a trifluormethyl group,  $(C_{1-4})$  alkoxy group,  $(C_{1-4})$  alkyl group; or wherein two neighbouring substituents may form a  $(C_{1-3})$  alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5; or pharmaceutically acceptable salts thereof;

for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.

2. The use according to claim 1, wherein  $R_1$  is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a  $(C_{1-5})$  alkoxy group, a  $(C_{1-5})$  alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. The use according to claim 2, wherein  $R_1$  is a residue derived from Phe which may optionally be substituted by a  $(C_{1-5})$  alkoxy group, a  $(C_{1-5})$  alkyl group or a halogen atom.

4. The use according to any of the preceding claims, wherein X is  $(C_{1-5})$  alkoxy,  $NH_2$ ,  $NH-C_{1-5}$ -alkyl, or  $N(C_{1-5}$  alkyl) $_2$ .

5. The use according to any of the preceding claims, wherein  $R_2$  is a residue derived from the amino acid Gly or Ile.

6. The use according to any of the preceding claims, wherein  $R_0$  is a cinnamoyl moiety.

7. The use according to any of the preceding claims, wherein the compound of formula (I) is cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-

L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.